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Introduction: The approach to thyroid hormone replacement varies across centres, 
but the extent and determinants of variation is unclear. We evaluated geographi-
cal variation in levothyroxine (LT4) and liothyronine (LT3) prescribing across General 
Practices in England and analysed the relationship of prescribing patterns to clinical 
and socioeconomic factors.
Methods: Data	was	downloaded	from	the	NHS	monthly	General	Practice	Prescribing	
Data in England for the period 2011- 2020.
Results: The study covered a population of 19.4 million women over 30 years of age, 
attending 6,660 GP practices and being provided with 33.7 million prescriptions of 
LT4 and LT3 at a total cost of £90million/year. Overall, 0.5% of levothyroxine treated 
patients	continue	to	receive	liothyronine.	All	Clinical	Commission	Groups	(CCGs)	in	
England continue to have at least one liothyronine prescribing practice and 48.5% 
of English general practices prescribed liothyronine in 2019- 2020. Factors strongly 
influencing more levothyroxine prescribing (model accounted for 62% of variance) 
were the CCG to which the practice belonged and the proportion of people with 
diabetes registered on the practice list plus antidepressant prescribing, with socio-
economic disadvantage associated with less levothyroxine prescribing. Whereas fac-
tors that were associated with increased levels of liothyronine prescribing (model 
accounted for 17% of variance), were antidepressant prescribing and % of type 2 dia-
betes	mellitus	individuals	achieving	HbA1c	control	of	58	mmol/mol	or	less.	Factors	
that were associated with reduced levels of liothyronine prescribing included smok-
ing and higher obesity rates.
Conclusion: In spite of strenuous attempts to limit prescribing of liothyronine in 
general practice a significant number of patients continue to receive this therapy, 
although there is significant geographical variation in the prescribing of this as for 
levothyroxine, with specific general practice and CCG- related factors influencing 
prescribing of both levothyroxine and liothyronine across England.
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution-	NonCommercial	License,	which	permits	use,	distribution	and	reproduction	
in any medium, provided the original work is properly cited and is not used for commercial purposes.
©	2021	The	Authors.	International Journal of Clinical Practice published by John Wiley & Sons Ltd.
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1  | INTRODUC TION
Primary hypothyroidism affects 2%- 5% of the general popula-
tion and is predominantly managed in the community.1 The major-
ity of individuals with hypothyroidism are effectively treated with 
levothyroxine (LT4), but a proportion of patients suffer persistent 
symptoms, despite achieving biochemical control with levels of free 
thyroxine	 (FT4)	 and	 thyroid-	stimulating	hormone	 (TSH)	within	 the	
laboratory reference ranges.2 Some patients who remain dissatisfied 
with LT4 therapy report improved well- being when prescribed com-
bination therapy with liothyronine (LT3) and LT4. LT3 represents the 
synthetic form of the metabolically active thyroid hormone and was 
originally widely prescribed when synthetic thyroid hormones first 
replaced	animal	thyroid	extracts	in	the	1950s.	However,	LT4	mono-
therapy has since prevailed as the treatment of choice for hypothy-
roidism because of its more favourable pharmacokinetic profile and 
once daily dosing schedule, coupled with the failure of randomised 
controlled trials to show superiority of combination therapy over LT4 
alone. Furthermore, early clinical studies used unduly high doses of 
LT3 that sometimes resulted in unpleasant adverse effects from iat-
rogenic thyrotoxicosis.3
Accordingly,	 existing	 clinical	 guidelines	 do	 not	 support	 the	
routine use of LT3 in the management of hypothyroidism.4- 6 The 
2016	 British	 Thyroid	 Association	 (BTA)	 position	 statement	 rec-
ommends that a trial of combination therapy can be considered 
in patients who unambiguously do not derive symptomatic bene-
fit from LT4 alone,6 a position that is broadly consistent with the 
guidelines	of	the	European	and	American	Thyroid	Associations.4,5 
In	the	UK,	LT3	prescribing	has	additionally	been	restricted	by	se-
rial price increases following transition from the proprietary to the 
generic product in 2007.7 Cost considerations have in recent years 
prompted a series of local prescribing policies aimed at curtailing 
LT3 prescribing. In the wake of these policies, an analysis by Taylor 
et al1 noted a substantial fall in LT3 use in England, a trend that 
varied geographically and was more pronounced in economically 
deprived	 areas.	 However,	 the	 drivers	 of	 thyroid	 hormone	 pre-
scribing at practice level and the extent of prescribing variation 
for both LT4 and LT3 are unclear. In the present study, we evalu-
ated geographical variation in LT4 and LT3 prescribing at general 





roid hormone prescriptions at general practice level in England for 
the period 2019- 2020. The study was conducted on data from the 
National	 Health	 Service	 (NHS)	 operational	 year	 April	 2019–	Mar	
2020, around which data is normally collated.
Information on practice populations and patient distribution by 
age and sex was obtained from the General Practice registration 
dataset.7 This dataset contains a record of all registered patients in 
GP practices in England broken down by age- bands and sex within 
Clinical Commissioning Group (CCG) areas. In addition, we collated 
data	 from	 the	 NHS	 general	 practice	 workforce	 statistics	 dataset	
comprising information on staff numbers including GPs, nurses and 
other clinical and non- clinical staff working in general practices in 
England.8 The Quality Outcome Frameworks dataset was used to 
document chronic disease prevalence, care quality indicators, as well 
as social deprivation measures and urban/rural location of the gen-
eral practice.9	We	also	extracted	practice	level	data	from	the	NHS	
General practice patient survey on rates of patient satisfaction and 
confidence in chronic disease management as well as ethnicity data 
for each practice.10
Medication	 use	 (LT4,	 LT3	 and	 antidepressants)	 was	 obtained	
from published practice- level monthly prescriptions issued by the 
NHS	 Business	 Service	 Authority.	 Prescriptions	were	 extracted	 by	
dose and British National Formulary (BNF) code7 and quantified 
according to the Defined Daily Dose (DDD).11 DDD is a standard 
method of comparing doses of a given medication and is taken as 
the average maintenance dose per day of a drug administered for 
its main indication in adults.11 The amount of active agent was con-
verted to defined daily doses by applying the levels given in the 
World	Health	Organisation	 and	Anatomical	 Therapeutic	 Chemical	
(WHO/ATC)	 classification.11 For LT3 which is most often used in 
combination with levothyroxine, an adjusted dose of 20 mcg/day 
was	applied	and	for	LT4	100	mcg/day	was	used.	All	the	data	used	in	




have imposed significant restrictions on liothyronine 
prescribing in general practice driven by the prohibitive 
costs and uncertain benefits of liothyronine in the man-
agement of hypothyroidism.
•	 However,	 the	 impact	 of	 these	 policies	 on	 liothyronine	
usage and costs are still unclear.
What’s new
• In spite of strenuous attempts to limit prescribing of 
liothyronine in general practice, a significant number of 
patients continue to receive this therapy, although there 
is significant geographical variation in the prescribing of 
this, as for levothyroxine with general practice and clini-
cal commissioning group (CCG) level factors a significant 
determinant.
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2.2 | Data analysis
As	 the	prevalence	of	hypothyroidism	 is	higher	 in	women,	we	cali-
brated prescribing of thyroid hormone replacement against the 
number of women in each general practice older than 30 years. In 
other words, the number of prescriptions as DDD was normalised 
for comparison between general practices by the number of women 
aged over 30 years old12 as this 38% of the population contains 85% 
of the patients with hypothyroidism.13 The gender and age mix for 
each practice were taken from the population data at general prac-
tice	level.	A	multivariate	regression	model	was	used	to	identify	the	
possible drivers of LT4 and LT3 prescribing. The outcome variables 
were (a) the amount of LT4 prescribed as a percentage of women 
aged >30 years, and (b) the amount of LT3 prescribed as a percent-
age of LT4 prescriptions.
The factors included in the model were as follows: (1) the local 
population characteristics (age, gender, ethnicity, social depriva-
tion, location, urban vs rural, north vs south, east vs west); (2) the 
chronic disease burden of the population (rates of hypertension, 
diabetes, chronic obstructive pulmonary disease (COPD), asthma, 
cancer, depression and antidepressant prescription); (3) the general 
practitioner characteristics (age, gender, country of qualification); (4) 
general practice service performance based on levels of glycosylated 
haemoglobin	HbA1c	control	reported	in	the	national	diabetes	audit	
(NDA);	 and	 (5)	 the	 patient	 survey	 feedback	 regarding	 service	 sat-
isfaction and patient confidence in managing their own long- term 
conditions.
The stepwise regression was first run with the all the local GP 
practice factors and then to establish the effect of the CCG. The 
local average CCG value for each prescribing variable was added as 
an additional factor for each practice into the stepwise regression 
to determine how much of the variation in local practices could be 
explained by their local CCG average for LT4 and LT3 prescribing. 
The difference in r2 and standardised beta value for the CCG aver-
age was an indicator of the size of impact of the CCG on the model. 
All	analyses	were	conducted	on	64	bit	excel	with	power	pivot	and	
Analyse-	it	add	 in	 (Microsoft	EXCEL).	Χ2 test was used to compare 
proportions.	A	P value < .05 was considered significant.
3  | RESULTS
The study covered a population of 19.4 million women over 30 years 
of age, attending 6660 GP practices and being provided with 33.7 
million prescriptions of LT4 and LT3 at a total cost of £90 million/
year.
3.1 | Variation in LT4 and LT3 prescribing (Figure 1)
In England, there are 135 local clinical commissioning groups of 
different population sizes. There was some variation in the iden-
tification and treatment of hypothyroidism with LT4 across differ-
ent CCGs: the median was 7.0% of the population of women age 
>30 years. The lowest decile region was 5.5% while the highest 
decile was 8.3% of women >30 years old (factorial variation of 1.5). 
Variation in use of LT3 was higher. The median was 0.4% of those 
being treated with Levothyroxine. The lowest decile was 0.1% while 
the highest decile was 1.4% of those treated with LT4 (factorial vari-
ation	of	14.0)	(Figure	1).	All	CCGs	had	at	 least	one	LT3	prescribing	
practice, with 51.5% of general practices not prescribing any LT3.
3.2 | Geographical variation by CCG (Figure 2)
There was a significant geographical variation across CCGs in 
England in rates of both LT4 and LT3 prescribing— adjusted for the 
proportion of women over the age of 30 in each CCG. In some areas 
such	as	the	South-	West,	Herefordshire	and	Lincolnshire,	higher	pre-
scribing of LT4 mapped to higher LT4 prescribing. In other areas such 
F I G U R E  1   Variation in prescribing by 
general practices in England in 2019/2020 
for levothyroxine (blue line) and for 
liothyrinone (orange line). The left hand 
y- axis is the percentage of women aged 
>30 years on levothyroxine, and the right 
hand y- axis is the percentage of people 
on thyroid replacement treatment taking 
liothyronine.	ADDD,	annual	defined	daily	
dose
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as North Cumbria and County Durham, there was relatively high 
prescribing of LT4 but not LT3. Conversely in some areas such as 
Cheshire	and	Kent	and	Medway	there	was	relatively	high	LT3	pre-
scribing and lower prescribing of LT4.
Overall there are more CCGs in the North of England (defined 
as a latitude more northerly than 52.6 degrees north) in the lowest 
tertile of LT3 prescribing, Χ2 3.4, P = .008 (Table 1).
3.3 | Regression modelling
3.3.1 | Levothyroxine	prescribing	(Figure	3)
For local levels of levothyroxine excluding the effects of CCG guid-
ance, the stepwise regression analysis could explain 54% of the 
variation	 between	 practices.	When	CCG	 average	 for	 ADDD	 levo-
thyroxine as percentage of population women age >30 years was 
included as a factor, the regression model could explain 62% of the 
variation between general practices, the CCG component having a 
standardised beta of 0.38 and so the strongest impact. Other factors 
related to more LT4 prescribing were the proportion of older women 
in the general practice, the proportion of people registered with dia-
betes and chronic obstructive pulmonary disease at a general prac-
tice and the proportion of older general practitioners in the practice. 
A	 significant	 factor	 positively	 associated	with	more	 levothyroxine	
prescribing was the rate of antidepressant prescribing. Factors as-
sociated with less prescribing of LT4 included a higher proportion 
of people with significant social disadvantage, higher smoking rates 
and	a	higher	proportion	of	people	of	black	and	ethnic	minority	(BME)	
ethnicity. General practices relatively more northerly in location 
tended to prescribe less levothyroxine.
3.3.2 | Liothyronine	prescribing	(Figure	4)
For local levels of LT3 prescribing, we considered all practices includ-
ing those that prescribed none. The base analysis of local factors 
could only explain 6% of the variation between practices, however, 
by including the CCG average value effect, the stepwise regres-
sion analysis could explain 17% of the variation between practices, 
with the CCG component having a standardised beta of 0.34. Other 
factors that were associated with increased levels of LT3 prescribing 
were rates of antidepressant prescribing and percentage of type 2 
diabetes	mellitus	 individuals	achieving	HbA1c	control	of	58	mmol/
mol or less. Factors that were associated with reduced levels of LT3 
prescribing included smoking and obesity rates and diabetes preva-
lence on the practice list.
3.3.3 | Comparison	of	factors	related	to	
levothyroxine and liothyronine prescribing
The main discretionary drivers of local thyroid prescribing for both 
levothyroxine and liothyronine were local CCG guidance, and prac-
tice	use	of	antidepressant.	However	the	impact	of	CCG	guidance	on	
liothyronine prescribing was much greater than for levothyroxine 
with tripling of the r2. Specifically, this was much higher than for 
levothyroxine where r2 increased by 20% when the CCG factor was 
included.
3.3.4 | Year	on	year	prescribing
The R2 value for the factors relating to change in year on year pre-
scribing for levothyroxine (6%) and liothyronine (2%) were low, indi-
cating that the factors that we have access to (including which CCG 
they belong to) do not relate to difference in change in prescribing 
year on year, between practices (data not shown).
4  | DISCUSSION
Undetected	 hypothyroidism	 causes	 significant	morbidity	 and	may	
be complicated by cardiovascular disease, lipid disorders and neu-
rocognitive impairment. In pregnancy, uncorrected maternal hypo-
thyroidism increases risk of fetal loss, while neglected disease in the 
elderly may culminate in life- threatening metabolic decompensa-
tion. Furthermore, there remains a subset of individuals who report 
reduced quality of life with health needs that are not met with LT4. 
Despite a spate of recent guidelines and prescribing policies, the 
real- world approach to thyroid hormone replacement remains in-
consistent	and	driven	by	factors	that	are	still	unclear.	Here,	we	have	
evaluated variation in LT4 and LT3 prescribing across general prac-
tices in England and determined factors that influence prescribing.
We found significant variation in the use of LT3 and LT4 with a 
higher	degree	of	 variation	 seen	with	LT3	prescribing.	Although	all	
CCGs had at least one LT3 prescribing practice, about half of prac-
tices did not prescribe any LT3. The regression analysis indicated that 
the CCG that a general practice belongs to has the greatest influence 
on LT4 and LT3 prescribing. Other factors related to increased LT4 
prescribing were the proportion of people registered with diabetes 
and chronic obstructive pulmonary disease at a general practice 
and rates of antidepressant prescribing. Interestingly, older general 
practitioners tended to prescribe more LT4. Factors associated with 
TA B L E  1   North vs South difference in LT4 and LT3 prescribing 
by CCG, described according to the number of CCGs in the lowest 







Number CCGs in Lowest Tertile for 
Levothyroxine as % Women >30
16 29
Number CCGs in Lowest Tertile for 
Liothyronine % Levothyroxine
30 15
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less LT4 prescribing included the proportion of people with obesity 
and of people with significant socioeconomic deprivation. For LT3, 
factors that were associated with increased prescribing were antide-
pressant use and the percentage of individuals with type 2 diabetes 
achieving	HbA1c	control	of	58	mmol/mol	or	less,	whereas	obesity,	
diabetes and smoking were associated with reduced prescribing.
In spite of strenuous attempts to limit LT3 prescribing in gen-
eral practice, our findings show that a significant number of doc-
tors continue to prescribe LT3. In England priorities for primary 
care are set by the local CCGs of which there are 135 of different 
sizes. Notably, all CCGs had at least one LT3 prescribing practice, 
suggesting a continued need for LT3 whether driven by patients or 
F I G U R E  2   (A)	Map	of	Variation	in	levothyroxine	and	liothyronine	prescribing	in	England	by	CCG.	(B)	The	key	to	the	England	CCG	map	
with each numbered CCG described
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their	clinicians.	Although	cost	considerations	have	led	to	prescrib-
ing policies designed to reduce LT3 prescription, the continued 
use of LT3 may have been encouraged by various sets of guidance 
published in the last decade4- 6 that now allow LT3 prescriptions 
in carefully selected individuals. Rates of LT4 prescribing on the 
other hand are influenced by differing views on the laboratory 
TSH	 thresholds	 for	 LT4	 initiation.13	 Although	 these	 thresholds	
have progressively reduced over the years,14 our results suggest 
that there is a significant variation with respect to screening and 
treatment initiation in patients with hypothyroidism. The influence 
F I G U R E  2   Continued
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of CCGs through local medicine management committees appear 
to play an over- riding role in the approach to both LT3 and LT4 
prescribing.
The increased LT4 prescribing seen in association with comor-
bidities like diabetes, chronic obstructive pulmonary disease and 
depression may reflect frequent testing and diagnosis in these 
groups of patients due to their more frequent contact with gen-
eral practice. The association of both LT4 and LT3 prescribing to 
rates of antidepressant prescribing may as alluded be a measure of 
how an individual general practice may be attuned to their practice 
population in relation to the realities of living with long- term con-
ditions and their consequences.15 In addition, patients with depres-
sion are more likely to have frequent contacts with their practices 
and therefore more likely to be tested for unresolved symptoms.15 
Reduced LT4 prescription was also seen with social deprivation, 
practices in more northern regions of England, and black and ethnic 
minority individuals suggesting inequalities in care access. Similar 
variations were reported by Taylor et al.1 Thus 50 years after the 
seminal paper by Taylor et al in 1970,16 the combination of LT4 and 




data collated at a national level, better to understand the factors 
influencing thyroid hormone prescribing across all CCGs in England. 




cifically evaluated the prescribing of NDT which is used by a small 
proportion of patients with hypothyroidism.
F I G U R E  3  Factors	independently	linked	with	levothyroxine	prescribing	in	England.	ADDD,	annual	defined	daily	dose;	AST,	Asthma;	BME,	
black	and	minority	ethnicity;	CAN,	cancer;	CCG,	Clinical	Commissioning	Group;	COPD,	chronic	obstructive	pulmonary	disease;	DM,	diabetes	
mellitus;	GP	workforce	HC,	General	Practitioner	Workforce	Head	Count;	QOF,	Quality	Outcome	Framework
F I G U R E  4  Factors	independently	linked	with	liothyronine	prescribing	in	England:	AD,	antidepressant;	BMI,	body	mass	index;	ADDD,	
annual	defined	daily	dose;	CCG,	Clinical	Commissioning	Group;	QOF,	Quality	Outcome	Framework;	T2DM,	diabetes	mellitus
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The matter of longitudinal trends in prescribing LT4 and LT3 in 
England is the subject of a separate paper.17
4.2 | Conclusion
There is significant geographical variation in the prescribing of LT4 and 
LT3 in general practice, The CCG where any general practice is located 
appears to be the over- riding influence on thyroid hormone prescribing 
with the influence much greater for LT3 than for LT4 prescribing.
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